A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies

Mitsune Tanimoto; Ryuzo Ohno; Yukio Kato; Junki Takamatsu; Eiji Watanabe; Hisamitsu Suzuki; Yasuo Morishtma; Htdeo Takeyama; Masahide Kobayashi; Kanji Ogata; Yoshthisa Kodera; Kohji Ezaki; Kohet Kawashtma; Tadasht Kamtya; Saburo Minami; Haruya Yoshtkawa; Hiroshi Nishiwaki; Satoshi Yoshikawa; Kazumasa Yamada

A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies

Mitsune Tanimoto, Ryuzo Ohno, Yukio Kato, Junki Takamatsu, Eiji Watanabe, Hisamitsu Suzuki, Yasuo Morishtma, Htdeo Takeyama, Masahide Kobayashi, Kanji Ogata, Yoshthisa Kodera, Kohji Ezaki, Kohet Kawashtma, Tadasht Kamtya, Saburo Minami, Haruya Yoshtkawa, Hiroshi Nishiwaki, Satoshi Yoshikawa, Kazumasa Yamada

Graduate School of Medicine Dentistry and Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

N⁴-Behenoy1-1-β-D-arabinofuranosy1cytosine (BH-AC) was administered to 11 patients with acute leukemia and five patients with other malignancies in a Phase I and TI clinical trial. Among 16 patients, 14 received BH-AC after being refractory to prior therapies, and two with acute leukemia received BH-AC for their first remission induction therapy.The starting dose was 1.5mg/kg administered as a single i.v. infusion of three hours. The doses were then escalated up to 5.0 mg/kg. No side effects were noted with single i.v. infusions. Daily consecutive infusions of 2.0 mg to 6.0 mg/kg for four to 21 days resulted in two patients experiencing nausea, two anorexia and one developing skin eruptions. Significant hematological effects were noted by the daily infusions. One patient with acute myeloblastic leukemia achieved complete remission with 5.0 mg/kg BH-AC administered daily for 21 days.BH-AC is active in acute leukemia and may play a role in the combination regimens for this disease.

Original language	English
Pages (from-to)	153-160
Number of pages	8
Journal	Japanese journal of clinical oncology
Volume	8
Issue number	2
Publication status	Published - Dec 1978

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Tanimoto, M., Ohno, R., Kato, Y., Takamatsu, J., Watanabe, E., Suzuki, H., Morishtma, Y., Takeyama, H., Kobayashi, M., Ogata, K., Kodera, Y., Ezaki, K., Kawashtma, K., Kamtya, T., Minami, S., Yoshtkawa, H., Nishiwaki, H., Yoshikawa, S., & Yamada, K. (1978). A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies. Japanese journal of clinical oncology, 8(2), 153-160.

Tanimoto, M, Ohno, R, Kato, Y, Takamatsu, J, Watanabe, E, Suzuki, H, Morishtma, Y, Takeyama, H, Kobayashi, M, Ogata, K, Kodera, Y, Ezaki, K, Kawashtma, K, Kamtya, T, Minami, S, Yoshtkawa, H, Nishiwaki, H, Yoshikawa, S & Yamada, K 1978, 'A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies', Japanese journal of clinical oncology, vol. 8, no. 2, pp. 153-160.

@article{f41e5d0d7aee4fe0903ee302f28437b5,

title = "A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies",

abstract = "N4-Behenoy1-1-β-D-arabinofuranosy1cytosine (BH-AC) was administered to 11 patients with acute leukemia and five patients with other malignancies in a Phase I and TI clinical trial. Among 16 patients, 14 received BH-AC after being refractory to prior therapies, and two with acute leukemia received BH-AC for their first remission induction therapy.The starting dose was 1.5mg/kg administered as a single i.v. infusion of three hours. The doses were then escalated up to 5.0 mg/kg. No side effects were noted with single i.v. infusions. Daily consecutive infusions of 2.0 mg to 6.0 mg/kg for four to 21 days resulted in two patients experiencing nausea, two anorexia and one developing skin eruptions. Significant hematological effects were noted by the daily infusions. One patient with acute myeloblastic leukemia achieved complete remission with 5.0 mg/kg BH-AC administered daily for 21 days.BH-AC is active in acute leukemia and may play a role in the combination regimens for this disease.",

author = "Mitsune Tanimoto and Ryuzo Ohno and Yukio Kato and Junki Takamatsu and Eiji Watanabe and Hisamitsu Suzuki and Yasuo Morishtma and Htdeo Takeyama and Masahide Kobayashi and Kanji Ogata and Yoshthisa Kodera and Kohji Ezaki and Kohet Kawashtma and Tadasht Kamtya and Saburo Minami and Haruya Yoshtkawa and Hiroshi Nishiwaki and Satoshi Yoshikawa and Kazumasa Yamada",

note = "Funding Information: 1-/3-D Arabinofuranosylcytosine (ara-C) is the main stay of the treatment for acute myelofienous leukemia in adults (Ellison et al., 1966). It has, however, several dis- Received October 14, 1978. This work is supported in part by Grants-in-Aid from the Ministry of Health and Wei-fare and from the Ministry of Education. Reprint requests: Mitsune Tanimoto, M.D., First Department of Internal Medicine, Nagoya University School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466, Japan.",

year = "1978",

month = dec,

language = "English",

volume = "8",

pages = "153--160",

journal = "Japanese Journal of Clinical Oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies

AU - Tanimoto, Mitsune

AU - Ohno, Ryuzo

AU - Kato, Yukio

AU - Takamatsu, Junki

AU - Watanabe, Eiji

AU - Suzuki, Hisamitsu

AU - Morishtma, Yasuo

AU - Takeyama, Htdeo

AU - Kobayashi, Masahide

AU - Ogata, Kanji

AU - Kodera, Yoshthisa

AU - Ezaki, Kohji

AU - Kawashtma, Kohet

AU - Kamtya, Tadasht

AU - Minami, Saburo

AU - Yoshtkawa, Haruya

AU - Nishiwaki, Hiroshi

AU - Yoshikawa, Satoshi

AU - Yamada, Kazumasa

N1 - Funding Information: 1-/3-D Arabinofuranosylcytosine (ara-C) is the main stay of the treatment for acute myelofienous leukemia in adults (Ellison et al., 1966). It has, however, several dis- Received October 14, 1978. This work is supported in part by Grants-in-Aid from the Ministry of Health and Wei-fare and from the Ministry of Education. Reprint requests: Mitsune Tanimoto, M.D., First Department of Internal Medicine, Nagoya University School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466, Japan.

PY - 1978/12

Y1 - 1978/12

N2 - N4-Behenoy1-1-β-D-arabinofuranosy1cytosine (BH-AC) was administered to 11 patients with acute leukemia and five patients with other malignancies in a Phase I and TI clinical trial. Among 16 patients, 14 received BH-AC after being refractory to prior therapies, and two with acute leukemia received BH-AC for their first remission induction therapy.The starting dose was 1.5mg/kg administered as a single i.v. infusion of three hours. The doses were then escalated up to 5.0 mg/kg. No side effects were noted with single i.v. infusions. Daily consecutive infusions of 2.0 mg to 6.0 mg/kg for four to 21 days resulted in two patients experiencing nausea, two anorexia and one developing skin eruptions. Significant hematological effects were noted by the daily infusions. One patient with acute myeloblastic leukemia achieved complete remission with 5.0 mg/kg BH-AC administered daily for 21 days.BH-AC is active in acute leukemia and may play a role in the combination regimens for this disease.

AB - N4-Behenoy1-1-β-D-arabinofuranosy1cytosine (BH-AC) was administered to 11 patients with acute leukemia and five patients with other malignancies in a Phase I and TI clinical trial. Among 16 patients, 14 received BH-AC after being refractory to prior therapies, and two with acute leukemia received BH-AC for their first remission induction therapy.The starting dose was 1.5mg/kg administered as a single i.v. infusion of three hours. The doses were then escalated up to 5.0 mg/kg. No side effects were noted with single i.v. infusions. Daily consecutive infusions of 2.0 mg to 6.0 mg/kg for four to 21 days resulted in two patients experiencing nausea, two anorexia and one developing skin eruptions. Significant hematological effects were noted by the daily infusions. One patient with acute myeloblastic leukemia achieved complete remission with 5.0 mg/kg BH-AC administered daily for 21 days.BH-AC is active in acute leukemia and may play a role in the combination regimens for this disease.

UR - http://www.scopus.com/inward/record.url?scp=77957211184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957211184&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77957211184

VL - 8

SP - 153

EP - 160

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -

A preliminary report of phase I and II study of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BH-AC) in patients with acute leukemia and other malignancies

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this